Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

David Younger notes that drug companies resist sharing proprietary historical data from past pipeline projects. Instead of asking members to dig into private vaults, A Alpha Bio's consortium focuses purely on forward-looking, pre-competitive experiments where participants design shared datasets with clear visibility before testing begins.

Related Insights

David Younger divides the data bottleneck into generalizable model training and proprietary candidate validation. Broad target and binder diversity can be generated collaboratively in pre-competitive pools, while validating clinical assets against specific proprietary drug targets remains entirely private and isolated outside the consortium.

Chai Discovery's partnership with Eli Lilly involves building a custom foundation model trained on Lilly's unique historical data. This signals a new collaboration model where AI firms act as specialized infrastructure builders, creating proprietary, data-moated AI for large pharmaceutical companies.

Despite competitors raising billions of dollars in the AI drug discovery sector, massive capital alone does not guarantee superior models. Many well-funded firms rely on retraining algorithms using the same publicly available crystal structure data. Generating unique, specialized experimental data at scale allows a lean startup to build more accurate predictive models while consuming a fraction of the funding.

The next inflection point will come from clever data generation strategies optimized for AI models, not human analysis. This "black box data" approach—like pooled screening with sequencing readouts—is vastly more scalable and creates a powerful, proprietary moat for companies.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

The company's core strategy is "data-first," believing the true long-term differentiator in AI drug discovery is generating unique, high-quality experimental data, not just innovating on model architecture, which they see as prone to commoditization when trained on public data.

The traditional transactional model where AI companies purchase pharma data is ending. To resolve the stalemate where AI needs trial data and trials need validated AI, the industry is shifting to strategic partnerships. In these collaborations, both parties jointly generate evidence during trials, accelerating development and providing mutual benefit.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

David Younger explains that training generalizable protein design models requires hundreds of thousands of structural affinity landscapes. Even using high-throughput tools that measure a million affinities at once, funding that volume alone is nearly impossible for one firm, whereas a five-member consortium yields 28 million data points per year.

David Younger argues that federated learning relies on messy historical records and keeps participants isolated. In contrast, pooled data consortiums incentivize members to actively share experimental breakthroughs, because helping peer members design better assays directly increases the quality and volume of data distributed back to everyone.